tissue plasminogen activator

(redirected from Activase)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

tissue plasminogen activator

[¦tish·ü plaz‚min·ə·jən ′ak·tə‚vād·ər]
(medicine)
A proteolytic enzyme that can convert plasminogen to plasmin.
References in periodicals archive ?
Investigators discovered the existence of rubisco activase in 1985 and proved that it activates rubisco.
Crystallization will allow researchers to study the activase protein more closely, to visualize its structure, and possibly to manipulate its sequence so that it doesn't unravel at higher temperatures.
That's an interesting choice of figures, given that your Activase, priced at $2,200 per dose, is facing some competition from $1,700-a-dose Eminase, produced by Smithkline Beechman, and streptokinase, a $200-a-dose product put out by Astra Kabi.
They also found the opposite: Rubisco activase in plants native to colder regions is more stable in lower temperatures.
Submitted for review to the FDA an sBLA for Activase for use in catheter clearance.
Specifically, rubisco activase helps convert rubisco from its inactive form to its active state.
A bioengineered plasminogen activator, TNKase is similar to Activase, which is a recombinant version of naturally-occurring tissue plasminogen activator (t-PA).
Percentage of patients with 24 hour improvement on 0-90 Min 91-180 Min 0-180 Min NIHSS(*) Activase (n=144) 51% 43% 47% Placebo (n=147) 46% 33% 39% p Value 0.
Adapted from the NINDS t-PA Stroke Trial Protocol Guidelines and the Activase Package Insert, Genentech
Products of the company are marketed under various brand names such as Activase, Avastin, Cathflo Activase, Rituxan, Xolair, Tarceva, Pulmozyme, Genentech, Herceptin, Lucentis, Raptiva, TNKase and Nutropin among others.
The findings from the Pharmacor topic entitled Acute Ischemic Stroke reveal that, in the absence of new pharmacotherapies, drug-treatment rates in AIS in most markets under study will increase modestly over the next ten years as use of recombinant tissue plasminogen activator (rt-PA)/alteplase (Genentech's Activase, other brands) gradually increases, aided by a modestly-expanded treatment window.
She has led the alliance management function for numerous global strategic alliances, and has contributed to the approval and commercialization of several biologics, including Rituxan, Zevalin, Pulmozyme, and Activase.